These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Long-term outcomes analysis of low-dose-rate brachytherapy in clinically T3 high-risk prostate cancer. Agarwal M; Chhabra AM; Amin N; Braccioforte MH; Molitoris JK; Moran BJ Brachytherapy; 2018; 17(6):882-887. PubMed ID: 30143400 [TBL] [Abstract][Full Text] [Related]
6. Stereotactic Ablative Radiotherapy Versus Low Dose Rate Brachytherapy or External Beam Radiotherapy: Propensity Score Matched Analyses of Canadian Data. Loblaw A; Pickles T; Crook J; Martin AG; Vigneault E; Souhami L; Cury F; Morris J; Catton C; Lukka H; Cheung P; Sethukavalan P; Warner A; Yang Y; Rodrigues G; Clin Oncol (R Coll Radiol); 2017 Mar; 29(3):161-170. PubMed ID: 27780694 [TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen at 4 to 5 years after low-dose-rate prostate brachytherapy is a strong predictor of disease-free survival. Lo AC; Morris WJ; Lapointe V; Hamm J; Keyes M; Pickles T; McKenzie M; Spadinger I Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):87-93. PubMed ID: 24331654 [TBL] [Abstract][Full Text] [Related]
8. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy. Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen Z; Lief JH; Adamovich E Urology; 2005 Jan; 65(1):95-100. PubMed ID: 15667872 [TBL] [Abstract][Full Text] [Related]
9. PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure. Ko EC; Stone NN; Stock RG Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):600-7. PubMed ID: 21985944 [TBL] [Abstract][Full Text] [Related]
13. Pretreatment 3T multiparametric MRI staging predicts for biochemical failure in high-risk prostate cancer treated with combination high-dose-rate brachytherapy and external beam radiotherapy. Hegde JV; Demanes DJ; Veruttipong D; Raince J; Park SJ; Raman SS; Nickols NG; King CR; Kishan AU; Steinberg ML; Kamrava M Brachytherapy; 2017; 16(6):1106-1112. PubMed ID: 28807747 [TBL] [Abstract][Full Text] [Related]
14. Low dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy: practice and outcome analysis in a series of 2237 patients from 11 institutions. Fellin G; Mirri MA; Santoro L; Jereczek-Fossa BA; Divan C; Mussari S; Ziglio F; La Face B; Barbera F; Buglione M; Bandera L; Ghedi B; Di Muzio NG; Losa A; Mangili P; Nava L; Chiarlone R; Ciscognetti N; Gastaldi E; Cattani F; Spoto R; Vavassori A; Giglioli FR; Guarneri A; Cerboneschi V; Mignogna M; Paoluzzi M; Ravaglia V; Chiumento C; Clemente S; Fusco V; Santini R; Stefanacci M; Mangiacotti FP; Martini M; Palloni T; Schinaia G; Lazzari G; Silvano G; Magrini S; Ricardi U; Santoni R; Orecchia R Br J Radiol; 2016 Sep; 89(1065):20150981. PubMed ID: 27384381 [TBL] [Abstract][Full Text] [Related]
15. The clinical significance of persistent cancer cells on prostate biopsy after high-dose-rate brachytherapy boost for intermediate-risk prostate cancer. D'Alimonte L; Helou J; Sherman C; Loblaw A; Chung HT; Ravi A; Deabreu A; Zhang L; Morton G Brachytherapy; 2015; 14(3):309-14. PubMed ID: 25466361 [TBL] [Abstract][Full Text] [Related]
16. A combined single high-dose rate brachytherapy boost with hypofractionated external beam radiotherapy results in a high rate of biochemical disease free survival in localised intermediate and high risk prostate cancer patients. Joseph N; Taylor C; O'Hara C; Choudhury A; Elliott T; Logue J; Wylie J Radiother Oncol; 2016 Nov; 121(2):299-303. PubMed ID: 28029404 [TBL] [Abstract][Full Text] [Related]
17. Does prostate-specific antigen nadir predict longer-term outcomes of prostate cancer after neoadjuvant and adjuvant androgen deprivation therapy in conjunction with brachytherapy? Morris LM; Izard MA; Wan WY Brachytherapy; 2015; 14(3):322-8. PubMed ID: 25487524 [TBL] [Abstract][Full Text] [Related]
18. Comparison of Image-Guided Intensity-Modulated Radiotherapy and Low-dose Rate Brachytherapy with or without External Beam Radiotherapy in Patients with Localized Prostate Cancer. Tsubokura T; Yamazaki H; Masui K; Sasaki N; Shimizu D; Suzuki G; Nakamura S; Yamada K; Okihara K; Shiraishi T; Yoshida K; Nishikawa T; Okabe H Sci Rep; 2018 Jul; 8(1):10538. PubMed ID: 30002393 [TBL] [Abstract][Full Text] [Related]
19. Permanent prostate brachytherapy monotherapy with I-125 for low- and intermediate-risk prostate cancer: Outcomes in 974 patients. Routman DM; Funk RK; Stish BJ; Mynderse LA; Wilson TM; McLaren R; Harmsen WS; Mara K; Deufel CL; Furutani KM; Haddock MG; Pisansky TM; Choo CR; Davis BJ Brachytherapy; 2019; 18(1):1-7. PubMed ID: 30293836 [TBL] [Abstract][Full Text] [Related]
20. Twelve-month prostate-specific antigen values and perineural invasion as strong independent prognostic variables of long-term biochemical outcome after prostate seed brachytherapy. Ding W; Lee J; Chamberlain D; Cunningham J; Yang L; Tay J Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):962-7. PubMed ID: 22494584 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]